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This study was designed to enhance our understanding of how reactive oxygen species 
(ROS), generated ex-situ by ionized gas (plasma), can affect the regulation of signalling 
processes within cells. A model system, comprising of a suspension of phospholipid vesicles 
(cell mimics) encapsulating a ROS reporter, was developed to study the plasma delivery of 
ROS into cells. For the first time it was shown that plasma unequivocally delivers ROS into 
cells over a sustained period and without compromising cell membrane integrity. An 
important consideration in cell and biological assays is the presence of serum, which 
significantly reduced the transfer efficiency of ROS into the vesicles. These results are key to 
understanding how plasma treatments can be tailored for specific medical or biotechnology 
applications. Further, the phospholipid vesicle ROS reporter system may find use in other 
studies involving the application of free radicals in biology and medicine. 
 
 
 
 
 
 
 
 
 
The direct application of plasma (ionized gas) to living tissue has potential in wound care [1], 
cancer treatment [2], disinfection [3], dentistry [4] and regenerative medicine [5]. 
Encouraging results over the past decade has included successful randomized clinical trials 
[6, 7]. These exciting results provide a solid basis for claims of a new medicinal technology, 
termed ‘plasma medicine’ [8].  
 
Inert gas plasmas impinging on, or mixed with air, are rich sources of reactive oxygen and 
nitrogen species (RONS) [8]. Perhaps, as a consequence of this, the efficacious effects of 
plasmas (when applied to tissue) are often linked to the RONS generated or delivered by the 
plasma to the biological target. Many of the RONS produced by plasma are also produced in 
vivo; within inter- and intra- cellular environments and are known to regulate key 
biochemical pathways, inducing chemical and physical changes in cells [9-13]. In a recent 
review, Graves summarised how plasma-generated RONS might activate / deactivate a 
number of well-established biological processes [13].  
 
Experiments have been devised to demonstrate the role of plasma generated RONS in cell 
proliferation, migration and angiogenesis [14-17] and to provide insight into the mechanisms 
involved in the plasma deactivation of bacteria [18-20] and tumours [2, 21, 22]. Although 
plausible hypotheses for the successful application of plasma to medical treatment are being 
advocated, there remains a major chasm between the plasma-induced ‘biological outcomes’ 
and a fundamental, underpinning knowledge of how plasma-generated RONS interact with 
cells and tissue. 
 
In order to address this issue, we developed a ‘tissue model’ to study the plasma interactions 
with phospholipid vesicles (mimics of cell membranes) encapsulated within a gelatin matrix 
(surrogate of tissue) [23]. We discovered that plasma can rupture vesicles > 150 m below 
the gelatin surface. Recently, we showed that plasma delivers ROS from 150 m to 1.5 mm 
into gelatin [24]. However, we could not unambiguously claim that plasma-derived reactive 
oxygen species (ROS) or reactive nitrogen species (RNS) can interact with cells in a hydrated 
biological environment.  
 
In this study, we focus on the plasma jet delivery of ROS into phospholipid vesicles (i.e. 
artificial cells) suspended in 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 
solution (pH 7.4). Specifically, we compared the plasma delivery of ROS into vesicles to 
treatments with hydrogen peroxide (H2O2). H2O2 is a  signalling molecule produced in many 
(possibly all) tissues in vivo [10]. When used as an exogenous ROS source, H2O2 can 
stimulate cell division at low concentrations (1 M) [25], but is cytotoxic at slightly higher 
concentrations (> 10 M) [10]. Biomedical plasma sources produce H2O2 in abundance in 
biological media from low (few M range) [26] to high (mM range) [27] concentrations.  
 
Vesicles (of 100 nm diameter) encapsulating 2,7-dichlorodihydrofluorescein (DCFH), a 
chemical indicator for a broad range of ROS [10], were used to monitor the plasma delivery 
of ROS into the vesicles in HEPES buffer at pH 7.4. Non-fluorescent DCFH is converted by 
ROS to the highly fluorescent 2,7-dichlorofluorescein (DCF) product [28, 29]. To investigate 
vesicle rupture, 50 mM of 5,6-carboxyfluorescein (CF) was encapsulated into 100 nm 
diameter vesicles. At this concentration, the dye is quenched inside the vesicles. The dye is 
released when the integrity of the membrane is compromised (e.g. from vesicle rupture or 
perforation), resulting in an increase in the fluorescence signal of CF. The artifical cell 
models are shown in scheme 1. Analysis of ROS and vesicle rupture were performed in two 
separate experiments because of the overlapping excitation / emission wavelengths for the 
dyes. Vesicles were treated with a plasma jet where helium gas is purged through a glass 
tube; the plasma is then ignited by supplying a high voltage potential across two external 
hollow electrodes surrounding the tube and the gas flow launches the plasma into the 
atmosphere (figure 1). The helium plasma jet was operated under conditions that produced a 
plasma plume of 5 mm in length into the ambient air (figure 1). Treatment was carried out 
using a relatively low flow rate of 100 ml / min and at a distance of 15 mm from the top of 
the test well to the end of the glass tube. Under these conditions, the plasma did not contact, 
and the gas flow did not disrupt, the surface of the test solution (as seen by the naked eye). 
We refer the reader to SI-1 (Supporting information) for a detailed description of the 
experimental methods. 
 
 
Figure 2a shows that the CF fluorescence intensity of the vesicle suspension did not increase 
immediately after plasma jet treatment for plasma jet treatment times (t) of 1, 5 and 10 min. 
Because the plasma jet treatment does not quench the fluorescence intensity of CF (i.e. no 
change in fluorescence was detected for unencapsulated CF in HEPES exposed to plasma, SI-
2 Supporting information), we can conclude that the CF dye was not released into the 
HEPES, and therefore the vesicle membranes were not lysed by the plasma jet treatment. On 
the other hand, the fluorescence intensity of the vesicles encapsulating DCFH increased as 
function of the plasma jet treatment time (i.e. dosage). Therefore, predominantly the plasma 
jet delivers ROS into the vesicles without damaging the vesicle membranes. The 
concentration of DCFH encapsulated within the vesicles was not a limiting factor in these 
experiments; in SI-3 (Supporting information) we show a further capacity of the dye to 
oxidise after two 10 min plasma jet treatments. Treatment with 1% (v/v) Triton X-100 
(surfactant that disrupts vesicles) confirmed the CF dye is released upon vesicle lysis and 
further, that rupture of the vesicles does not increase fluorescence of the DCFH ROS reporter 
(figure 2b). Treatment with the neutral helium gas (i.e. plasma off) had no effect on vesicle 
lysis or delivery of ROS (figure 2b). In addition to 100 nm-sized vesicles, the plasma jet 
readily delivered ROS into giant unilamellar vesicles (GUVs) of several m in diameter 
(approaching the dimension of a cell) without notable damage to the vesicle membrane (SI-4 
Supporting information).  
 
The next experiment was designed to study the effects of the longer-lived plasma ROS, 
without direct exposure to the plasma beam and to VUV / UV radiation (produced in the 
plasma jet); removal of the plasma beam removes very short-lived radicals. It is known that 
VUV / UV can induce chemical and physical changes in cells [8]. Diffusion of the plasma 
generated longer-lived ROS was compared to a relatively stable reactive species known to be 
generated by plasma (i.e. H2O2). HEPES (with no vesicles) was treated with the plasma jet 
and the plasma-activated liquid (PAL) was mixed with DCFH-containing vesicles. 
Approximately 56, 74 and 105 M of H2O2 was produced by the plasma jet treatment in 
HEPES for t = 1, 5 and 10 min, respectively (SI-5 Supporting information). Based upon the 
fluorescence intensity of oxidised DCFH, we deduce that a higher quantity of ROS was 
delivered inside the vesicles from the PAL in comparison to the corresponding concentrations 
of H2O2 solutions (figure 3a-b). This result indicates that the PAL retains a heterogeneous 
mixture of longer-lived ROS that can participate in cell oxidation. These data were acquired 
immediately after plasma jet treatment (defined as 0 h). Even after 15 h of incubation, ROS in 
the PAL still diffused into the vesicles (figure 3a). This result indicates that plasma-generated 
ROS may in situ have appreciable half-lives such that plasma generated ROS could even 
oxidize new cells (generated from cell division) many hours after the initial plasma treatment.  
 
Although the above data show that a plasma jet generates ROS that interact with vesicles 
over a sustained period (without damage to the membrane), the in vivo situation could be 
somewhat different: the highly proteinaceous environment of the extracellular matrix may 
affect the delivery of ROS into cells. E.g. Tian et al showed through mathematical modelling, 
that plasma-derived ROS are largely ‘consumed’ by alkane hydrocarbons [30]. Furthermore, 
the serum of cell culture media contains amino acids that readily react with the plasma 
reactive species [31] and antioxidant enzymes such as catalase that protect cells against 
oxidation [32].  
 
We tested this by performing the plasma jet treatment on DCFH-containing vesicles in 
HEPES supplemented with two different concentrations of fetal bovine serum (FBS), which 
is a common additive in cell culture media. The level of DCFH oxidation within the vesicles 
was significantly reduced in HEPES containing 10% (v/v) FBS (figure 4). FBS is commonly 
used at 10% (v/v) for in vitro cell culture. Delivery of ROS into the vesicles was almost 
completely prevented in HEPES supplemented with a higher concentration of FBS at 50% 
(v/v). The plasma jet treatment did not lyse vesicles containing CF in HEPES supplemented 
with 10% or 50% (v/v) FBS (SI-6 Supporting information). Therefore, the reduced amount of 
ROS delivered by the plasma jet into the vesicles can be attributed to the reaction of ROS 
with the serum ingredients and / or from anti-oxidizing enzyme activity. 
 
Quantification of the ROS delivered by the plasma jet into cells is necessary to obtain a firm 
link between the role of plasma generated ROS and cellular signalling processes. We adapted 
the formula from Loetchutinat et al to measure the plasma jet delivery of ROS into vesicles 
[33]:  
 
d[DCF]
dt
= kencap[DCFH][ROSi] 
 
 
 Here the rate of DCFH oxidation to DCF is d[DCF]/dt); the second order rate constant for 
oxidation of DCFH (with H2O2) is kencap (where encap refers to DCFH encapsulated within 
vesicles); the DCFH concentration is [DCFH] and the concentration of ROS inside the 
vesicles is [ROSi]. The [ROSi] was determined experimentally as detailed in SI-7 (Supporting 
information). The [ROSi] delivered by the plasma jet into the entire vesicle suspension 
seemed low (e.g. 3.32 x 10-8 M at 1 h after 1 min of plasma jet treatment, Table 1). However, 
this value converts to 0.633 x 10-4 M µm-3 when adjusted to moles / unit volume (Table 1). 
This is orders of magnitude higher than steady-state levels of ROS in cells at  1.26 x 10-12 
Mµm-3 (assuming a 10 µm diameter spherical cell) [33]. In comparison, a lower [ROSi] was 
measured in vesicles treated with PAL or H2O2; although these values are still well above 
steady-state ROS levels in cells (Table 1). Because a significant amount of plasma generated 
ROS can be delivered into cells, it is possible that plasma generated ROS may regulate 
cellular processes through the oxidation / modification of the internal cell components as 
opposed to more indirect mechanisms involving the modification of extracellular matrix 
biomolecules or the external cell membrane / receptors that in turn, leads to the up-regulation 
of ROS within the cell. We acknowledge that the cellular machinery is equipped to regulate 
ROS levels; however, we also note that it is energetically more favourable for cells to repair 
or replace damaged biomolecules rather than maintaining higher levels of antioxidant 
defences against ROS [10]. 
 
The long term goal (and major impact) is the use of plasma to synthetically generate RONS 
that intervene in known biological processes associated with disease or tissue regeneration 
[13]. This goal is based upon the capability to develop new medical therapies whereby 
plasma generated RONS are directly delivered to sites of disease or injury. This capability 
has the potential to exceed what can be achieved using conventional drug therapies. 
However, understanding the fundamental role of RONS and free radicals in biology and 
medicine is confounded by the complexity of the biological environment and intracellular 
signalling pathways and the difficulty to accurately detect and quantify RONS in the cell. 
Other effects, such as oxidative artefacts in cell culture media, can lead to misinterpretation 
of results [32]. Therefore, the ability to analyse the interactions of plasma generated RONS in 
model systems under controlled and repeatable conditions should significantly help in 
expediting our fundamental understanding of the role of plasma in medicine. This study 
shows that plasma delivers ROS into cells above steady-state levels in cells (as reported in 
the literature) and for a sustained period (at least 15 h). These results might be linked to the 
observed biological effects of plasma generated RONS such as plasma-induced wound 
healing, stem cell differentiation and cancer cell destruction. The phospholipid vesicle ROS 
reporter system may also find use in a range of other studies involving free radicals in 
biology and medicine. 
 
Acknowledgements 
The authors thank the Wound Management Innovation CRC for partially funding this work 
through project RP 2.11. The authors thank Bacteriosafe for providing the travel award that 
enabled us to carry out this research project, and EC-FP7 funding of programme 245500 
Bacteriosafe, EC grant: KOALA 295155. 
 
References 
[1] G. Lloyd, G. Friedman, S. Jafri, G. Schultz, A. Fridman, K. Harding, Plasma Process. 
Polym. 2010, 7, 194-211. 
[2] M. Keidar, A. Shashurin, O. Volotskova, M. A. Stepp, P. Srinivasan, A. Sandler, B. 
Trink, Phys. Plasma. 2013, 20, 057101-057108. 
[3] M. L. Burts, I. Alexeff, E. T. Meek, J. A. McCullers, Am. J. Infect. Control 2009, 37, 
729-733. 
[4] M. Miletić, S. Mojsilović, I. O. Đorđević, D. Maletić, N. Puač, S. Lazović, G. 
Malović, P. Milenković, Z. L. Petrović, D. Bugarski, J. Phys. D: Appl. Phys. 2013, 
46, 345401. 
[5] Z. Xiong, S. Zhao, X. Mao, X. Lu, G. He, G. Yang, M. Chen, M. Ishaq, K. Ostrikov, 
Stem Cell Res. 2014, 12, 387-399. 
[6] G. Isbary, J. Heinlin, T. Shimizu, J. L. Zimmermann, G. Morfill, H. U. Schmidt, R. 
Monetti, B. Steffes, W. Bunk, Y. Li, T. Klaempfl, S. Karrer, M. Landthaler, W. Stolz, 
Br. J. Dermatol. 2012, 167, 404-410. 
[7] G. Isbary, G. Morfill, H. U. Schmidt, M. Georgi, K. Ramrath, J. Heinlin, S. Karrer, M. 
Landthaler, T. Shimizu, B. Steffes, W. Bunk, R. Monetti, J. L. Zimmermann, R. 
Pompl, W. Stolz, Br. J. Dermatol. 2010, 163, 78-82. 
[8] M. G. Kong, G. Kroesen, G. Morfill, T. Nosenko, T. Shimizu, J. V. Dijk, J. L. 
Zimmermann, New J. Phys. 2009, 11, 115012. 
[9] B. Halliwell, J. M. Gutteridge, Biochem. J. 1984, 219, 1-14. 
[10] B. Halliwell, J. M. C. Gutteridge, Free radicals in biology and medicine, Oxford 
Univeristy Press, Oxford, 2007. 
[11] B. Halliwell, M. Whiteman, Br. J. Pharmacol. 2004, 142, 231-255. 
[12] A. E. K. Loo, Y. T. Wong, R. Ho, M. Wasser, T. Du, W. T. Ng, B. Halliwell, PLoS 
ONE 2012, 7, e49215. 
[13] D. B. Graves, J. Phys. D: Appl. Phys. 2012, 45, 263001. 
[14] K. P. Arjunan, G. Friedman, A. Fridman, A. M. Clyne, J. Royal Soc. Interf. 2012, 9, 
147-157. 
[15] K. P. Arjunan, A. Morss Clyne, Plasma Process. Polym. 2011, 8, 1154-1164. 
[16] S. Kalghatgi, G. Friedman, A. Fridman, A. Clyne, Ann. Biomed. Eng. 2010, 38, 748-
757. 
[17] M-H. T. Ngo, J-D. Liao, P-L. Shao, C-C. Weng, C-Y. Chang, Plasma Process. 
Polym. 2014, 11, 80-88. 
[18] S. G. Joshi, M. Cooper, A. Yost, M. Paff, U. K. Ercan, G. Fridman, G. Friedman, A. 
Fridman, A. D. Brooks, Antimicrob. Agents Chemother. 2011, 55, 1053-1062. 
[19] J. Goree, B. Liu, D. Drake, J. Phys. D: Appl. Phys. 2006, 39, 3479. 
[20] M. Laroussi, C. Tendero, X. Lu, S. Alla, W. L. Hynes, Plasma Process. Polym. 2006, 
3, 470-473. 
[21] M. Keidar, R. Walk, A. Shashurin, P. Srinivasan, A. Sandler, S. Dasgupta, R. Ravi, R. 
Guerrero-Preston, B. Trink, Br. J. Cancer 2011, 105, 1295-1301. 
[22] J. Y. Kim, Y. Wei, J. Li, P. Foy, T. Hawkins, J. Ballato, S.-O. Kim, Small 2011, 7, 
2291-2295. 
[23] S. E. Marshall, A. T. A. Jenkins, S. A. Al-Bataineh, R. D. Short, S.-H. Hong, N. T. 
Thet, J.-S. Oh, J. W. Bradley, E. J. Szili, J. Phys. D: Appl. Phys. 2013, 46, 185401. 
[24] E. J. Szili, J. W. Bradley, R. D. Short, J. Phys. D: Appl. Phys. 2014, 47, 152002. 
[25] R. H. Burdon, D. Alliangana, V. Gill, Free Radic. Res. 1994, 21, 121-133. 
[26]     T. Nosenko, T. Shimizu, G. E. Morfill, New J. Phys. 2009, 11, 115013. 
[27] U. K. Ercan, H. Wang, H. Ji, G. Fridman, A. D. Brooks, S. G. Joshi, Plasma Process. 
Polym. 2013, 10, 544-555. 
[28] A. Gomes, E. Fernandes, J. L. F. C. Lima, J. Biochem. Biophys. Methods 2005, 65, 
45-80. 
[29] S. P. Low, K. A. Williams, L. T. Canham, N. H. Voelcker, J. Biomed. Mater. Res. A 
2010, 93A, 1124-1131. 
[30] W. Tian, M. J. Kushner, J. Phys. D: Appl. Phys. 2014, 47, 165201. 
[31] E. Takai, T. Kitamura, J. Kuwabara, S. Ikawa, S. Yoshizawa, K. Shiraki, H. 
Kawasaki, R. Arakawa, K. Kitano, J. Phys. D: Appl. Phys. 2014, 47, 285403. 
[32] B. Halliwell, FEBS Letters 2003, 540, 3-6. 
[33] C. Loetchutinat, S. Kothan, S. Dechsupa, J. Meesungnoen, J.-P. Jay-Gerin, S. 
Mankhetkorn, Radiat. Phys. Chem. 2005, 72, 323-331. 
 
 
  
 
Figure 1. Photograph of the helium plasma jet in operation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2. Plasma jet delivers ROS non-destructively into phospholipid vesicles. (A) 
Normalized fluorescence intensity (FI) of 100 nm diameter vesicles encapsulating CF or 
DCFH after plasma jet treatment. (B) Normalized FI of vesicles encapsulating CF or DCFH 
after control treatments with Triton X-100 (positive control for vesicle lysis) and the 
neutral helium (i.e. plasma off). Helium 1, 5 and 10 in (B) refers to the helium treatment time. 
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Figure 3. Plasma generated ROS are long-lived and penetrate phospholipid vesicles over a 
sustained 15 h period. (A) Normalized fluorescence intensity (FI) of 100 nm diameter 
vesicles encapsulating DCFH after addition of the PAL. (B) Normalized FI of 100 nm 
vesicles encapsulating DCFH after addition of the H2O2 solutions. The H2O2 concentrations 
are matched to those measured in PAL; i.e. plasma jet treatment t of 1 = 56 µM, 5 = 74 μM 
and 10 = 105 μM. 
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 Figure 4. Efficiency of the plasma delivery of ROS into vesicles is significantly reduced in 
the presence of cell culture serum. Vesicles encapsulating DCFH in HEPES were treated with 
the plasma jet in the presence of 0%, 10% and 50% FBS. Plasma jet treatment was compared 
to treatment with the neutral helium (i.e. plasma off). 
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 Scheme 1. Diagrammatical representation of the artificial cell models (vesicles) used to study 
the plasma delivery of ROS into vesicles and plasma induced vesicle damage. Vesicles 
encapsulating 2,7-dichlorodihydrofluorescein (DCFH) were used to monitor the plasma 
delivery of ROS into vesicles, as shown on the left. Vesicles encapsulating 5,6-
carboxyfluorescein (CF) were used to assess if plasma treatment induced vesicle lysis, as 
shown on the right. 
 
 
 
 
 
 
 
 
 
Table 1. Concentration of ROS delivered into the vesicles by the plasma jet, from the 
plasma-activated liquid (PAL) and from the H2O2 solution. The plasma jet readily delivers 
ROS into vesicles at concentrations well above steady-state levels observed in cells.[a] 
 
Treatment 
condition 
[ROSi] @ 1h 
(x10-8 M) 
[ROSi] @ 1h per 
volume (x10-4 Mm-3) 
[ROSi] @ 15h 
(x10-8 M) 
[ROSi] @ 15h per 
volume (x10-4 Mm-3) 
Plasma Jet 1 3.32 
± 0.485 
0.633 
± 0.096 
4.13 
± 0.349 
0.788 
± 0.067 
Plasma Jet 5 16.5 
± 0.643 
3.14 
± 0.123 
19.2                     
± 1.67 
3.66 
± 0.318 
Plasma Jet 10 31.8 
± 2.40 
6.07 
± 0.458 
34.7                    
± 0.320 
6.63 
± 0.061 
PAL 1 4.29 
± 0.250 
0.819 
± 0.058 
5.22                   
± 0.024 
0.996 
± 0.005 
PAL 5 7.34 
± 0.361 
1.40 
± 0.069 
7.33                     
± 0.098 
1.40 
± 0.019 
PAL 10 8.62 
± 0.250 
1.65 
± 0.048 
8.88                   
± 0.083 
1.70 
± 0.016 
56 M H2O2 1.99 
± 0.043 
0.380 
± 0.008 
2.09                   
± 0.005 
0.399 
± 0.001 
74 M H2O2 2.09 
± 0.581 
0.399 
± 0.011 
2.16           
±0.004 
0.413 
± 0.001 
105 M H2O2 2.43 
± 0.276 
0.464 
± 0.005 
2.38                   
± 0.001 
0.455 
± 0.005 
[a]Steady-state levels of ROS calculated in cells from values provided by Loetchutinat et al 
[33] and assuming that the cell is spherical with a diameter of 10 µm. 
 
